Preventing disease
Growth factors (for example, GM-CSF and G-CSF) shorten the duration of neutropenia after HCT. 412 However, a meta-analysis showed that use of growth factors did not reduce the attack rate of invasive fungal disease 165 and, therefore, no recommendation can be made for the use of growth factors for prophylaxis against invasive fungal disease (CI).
Topical antifungal drugs applied onto the skin or mucosa (for example, nystatin or clotrimazole) might reduce colonization by yeasts and molds in the area of application. However, these agents have not been proven to prevent locally invasive or disseminated yeast or mold infections and their use for prophylaxis is unclear (CIII) . Performing fungal surveillance cultures is not indicated for asymptomatic HCT recipients (DII). 413, 414 Other recommendations Patients receiving antifungal prophylaxis who develop clinical signs or symptoms of infection should be evaluated for breakthrough bloodstream or pulmonary fungal infections (AIII). Such infections may occur because the prophylactic drug has no activity against the organism; because the organism has developed resistance to the drug; or because of other factors, such as severe immunosuppression or low serum levels of the prophylactic agent. 415 
Recommendations regarding yeast infections

Preventing exposure
The risk for invasive candidiasis is significantly higher during the early post transplant period (phase I) because of neutropenia, severe mucositis and the presence of a central venous catheter. 416 During phase II, the risk factors for invasive candidiasis are the presence of a central venous catheter and severe gastrointestinal GVHD. 416 Among autologous HCT recipients, the risk of invasive candidiasis is minimal once neutropenia and mucositis have resolved.
Invasive candidiasis is usually caused by dissemination of endogenous Candida species that have colonized a patient's gastrointestinal tract. 417 Consequently, the methods of preventing exogenous yeast exposure usually do not prevent invasive yeast infections after HCT. However, because Candida species can be carried on hands, health care workers and others in contact with HCT recipients should follow appropriate hand-washing practices to avoid exposing patients to fungal pathogens (AII).
Preventing disease
Fluconazole is the drug of choice for the prophylaxis of invasive candidiasis before engraftment in allogeneic HCT recipients, and may be started from the beginning or just after the end of the conditioning regimen (AI). 418, 419 Lowdose fluconazole has variable efficacy; therefore, doses lower than 200 mg are not recommended (DII). The optimal duration of fluconazole prophylaxis-specifically, whether prophylaxis confers significant benefits when continued after engraftment-is not defined. A post-hoc analysis of a randomized clinical trial has shown that fluconazole given until day 75 after transplant was associated with prolonged protection against invasive candidiasis, even beyond the period of prophylaxis.
420
Fluconazole is not effective against Candida krusei and has variable activity against C. glabrata, which can become resistant; 421 moreover, the use of fluconazole for prophylaxis may result in the selection of azole-resistant Candida species (principally C. glabrata and C. krusei).
422 Therefore, fluconazole is not recommended for the prevention of such infections (DI). This may be a consideration in patients who are known to be colonized with fluconazole-resistant Candida species.
Cross-resistance to azoles (that is, fluconazole, voriconazole, posaconazole) may occur among Candida species, particularly in C. glabrata.
423,424 Therefore, clinicians should be alert for the possibility of a breakthrough infection with resistant organisms in patients receiving prophylaxis with any azole drug (CIII).
Micafungin is an alternative prophylactic agent, as one study has shown it to be comparable with fluconazole for preventing possible or documented fungal infection (BI).
425
Use of micafungin as a prophylactic agent is limited by the necessity of i.v. infusion and cost. There have been case reports of sporadic resistance to echinocandin antifungal agents.
426
Itraconazole oral solution has been shown to prevent invasive fungal infections, but use of this drug is limited by poor tolerability and toxicities (CI). 427, 428 If antimold activity is warranted in antifungal prophylaxis, posaconazole and voriconazole are options. 429, 430 Posaconazole has not been studied in the preengraftment phase of HCT. Few HCT recipients require prophylaxis against Candida in the postengraftment period (phases II and III), but if needed (for example, due to the presence of GVHD), options include voriconazole (BI) 430 and posaconazole (BI).
429
Oral, nonabsorbable antifungal drugs, including oral amphotericin B (500 mg suspension every 6 h), nystatin and clotrimazole troches, might reduce superficial colonization and control local mucosal candidiasis, but have not been shown to reduce invasive candidiasis (CIII). Concern arising from the detection of potential pathogens in food has not been supported by documented evidence of such organisms as the source of opportunistic infections in immunocompromised persons. The potential benefit of food safety recommendations directed specifically toward HCT recipients must be weighed against the uncertain value of such recommendations 767 and their potential to adversely affect patients' nutritional intake and/or quality of life. a Though not completely risk free, the risk of contracting foodborne illness from cooked soft cheeses is low. b Shelf-stable refers to unopened canned, bottled or packaged food products that can be stored before opening at room temperature; container may require refrigeration after opening. c Aseptically packaged, shelf-stable tofu and pasteurized tofu do not need to be boiled. Non-pasteurized tofu must be cut into 1-inch cubes or smaller, and boiled a minimum of 5 min in water or broth before eating or using in recipes. d Rinse under clean, running water before use, including produce that is to be cooked or peeled (such as bananas, oranges and melon). e Bring tap water to a rolling boil and boil for 15-20 min. Store boiled water in the refrigerator. Discard water not used within 48 h (2 days). f Recommend using boiled or bottled water if using a water service other than city water service. Please see 'Water Safety Guidelines' in 'Food Safety Guidelines'. g See 'Water Safety Guidelines' in 'Food Safety Guidelines' for approved bottled water treatments. h Honey products are not allowed for any child aged o1 year and not allowed for children with SCID syndrome until 9 months post transplant.
Other recommendations
Hematopoietic cell transplantation candidates with candidemia or invasive candidiasis can safely receive transplants 431 if (a) their infection is diagnosed early and treated immediately and aggressively with effective anti-Candida therapy; and (b) there is evidence of infection control before the transplant (BIII). Such patients should continue receiving therapeutic doses of an appropriate antifungal drug throughout phase I (BII) and until a careful review of clinical, laboratory and serial computed tomography scans verifies the resolution of candidiasis (BII). As radiographic abnormalities may persist for a long period of time among patients with hepatosplenic candidiasis, complete resolution is not necessary before transplantation, provided that the patient has received appropriate therapy and shows clinical improvement.
As autologous recipients generally have an overall lower risk for invasive fungal infection than do allogeneic recipients, most autologous recipients do not require routine antiyeast prophylaxis (CIII). However, experts recommend administering antiyeast prophylaxis to a sub-population of autologous recipients who have underlying hematological malignancies (for example, lymphoma, leukemia or myeloma) and who have or will have prolonged neutropenia and mucosal damage from intense conditioning regimens or graft manipulation, or have received fludarabine or 2-CDA within 6 months before HCT (BIII). Recommendations regarding the prevention of invasive yeast infections are the same among pediatric and adult HCT recipients, except that appropriate dose adjustments for prophylactic drugs should be made for pediatric recipients (Appendix 1).
When considering the continuation of antifungal therapy in patients with an earlier infection, HCT clinicians should be mindful of drug interactions, especially with calcineurin inhibitors, particularly with drugs in the azole class, which affect cytochrome P450 metabolism. 432 Results of recent studies suggest differential toxicities and effects on CY metabolites with coadministration of different azole drugs. 432, 433 Specifically, coadministration of fluconazole was associated with fewer early toxicities and different metabolites compared with itraconazole. 433 This was hypothesized to be because of fluconazole inhibition of cytochrome P450 2C9 providing a 'protective' effect compared with that by itraconazole, which inhibits only P450 3A4. 432 In general, clinicians should be careful while coadministering drugs that impact any cytochrome subunits active in conditioning metabolism.
Recommendations regarding mold infections
Preventing exposure Nosocomial mold infections among HCT recipients result primarily from respiratory exposure to and direct contact with fungal spores. 434 Measures for minimizing exposure to mold in HCT candidates and recipients are discussed in the Infection Prevention and Control in Healthcare Facilities section.
In addition to air, water may also be a source of pathogenic fungi. Opportunistic molds (for example, Aspergillus and Fusarium species) are present in water and on water-related surfaces of hospitals caring for cancer patients, and molecular studies have suggested the potential relatedness of environmental and clinical strains among patients with aspergillosis and fusariosis. [435] [436] [437] Therefore, hospital water should be considered a potential source of nosocomial invasive mold infections. Although some investigators believe it to be necessary to decrease patient exposure during periods of severe immunosuppression, 438 current data are insufficient to support the formulation of definitive recommendations. Cleaning of water-related structures in patients' bathrooms may be attempted. 435, 436 Preventing disease Invasive mold infections have a trimodal incidence distribution among allogeneic HCT recipients. [439] [440] [441] Before engraftment (that is, during phase I), the main risk factor is prolonged neutropenia, and, therefore, the risk is higher with BM and umbilical cord blood transplants and lower with peripheral blood and nonmyeloablative transplants. In addition, the risk is higher among patients with prolonged low-level neutropenia before transplant, such as aplastic anemia patients. In phases II and III, the main risk factor is severe cell-mediated immunodeficiency caused by GVHD and its treatment. Therefore, recipients of transplants with higher risks for severe GVHD (unrelated donor, mismatched transplant, haploidentical) are at higher risk for mold infections. Patients at high risk for mold infections should be considered for prophylaxis with mold-active drugs during periods of risk (BI).
Trials assessing the efficacy of cyclodextrin oral solution and i.v. formulations of itraconazole have shown efficacy in preventing mold infections (BI), but the benefit was offset by poor tolerance and toxicity of the oral formulation, with B25% of the discontinuation attributed to gastrointestinal side effects. 427, 433 One study has shown micafungin to be effective in preventing invasive fungal infections (including fever) when administered during neutropenia, 425 but the incidence of invasive aspergillosis is low during the preengraftment phase, hence antimold efficacy could only show activity rather than efficacy (BI). Experience with other echinocandins (for example, caspofungin) shows some efficacy (CII), but breakthrough mold infections during echinocandin prophylaxis have been reported. 442 Fluconazole has no activity against molds. 443 On the basis of the results of a study presented to date, only in abstract form, 430 voriconazole seems to be an alternative to fluconazole prophylaxis. As the results of this study have not been presented in detail, the committee is not assigning a recommendation. Specific molds are resistant to certain drugs (for example, voriconazole does not have activity against zygomycetes, and Scedosporium prolificans is resistant to all available antifungal agents).
In patients with GVHD, posaconazole has been reported to prevent invasive mold infections (BI). 429 In one study, patients with GVHD were randomized to receive either fluconazole (400 mg) or posaconazole (200 mg thrice daily). Results showed a trend toward a lower incidence of invasive fungal infection, with particular differences in mold infections. The optimal duration of prophylaxis in the setting of GVHD is not defined.
Aerosolized liposomal amphotericin B has been found to be effective in reducing invasive pulmonary aspergillosis in one randomized trial that included leukemia and HCT patients, and can be considered as an alternative to moldactive azoles (BII). 444 However, administration of the drug was interrupted by cough in many patients, and the optimal aerosol dose and delivery device have not yet been determined. Thus, further study is needed before its role can be determined.
Other recommendations
Patients with an earlier invasive aspergillosis should receive secondary prophylaxis with a mold-active drug (AII). The optimal drug has not been determined, but voriconazole has been shown to have benefit for this indication (AII).
445
Recommendations regarding serum level monitoring Absorption of itraconazole and posaconazole is poor in patients who do not eat. Meta-analyses suggest that the efficacy of itraconazole is associated with bioavailability; blood levels of 40.5 mg/ml are associated with effective prevention of proven invasive fungal infection. 446 Posaconazole levels for therapeutic effectiveness have not been established. Median levels of posaconazole are relatively lower in patients who have acute GVHD and symptomatic diarrhea. 447 Voriconazole blood levels of at least 1 mg/ml are thought to be required for efficacy. Low voriconazole levels have been reported in patients with documented breakthrough infections. 415 There is relative controversy over the use of routine monitoring of azole drug levels, but most clinicians agree that measurement of levels should be considered in patients who have documented breakthrough infection. A change to, or addition of, an antifungal agent of a different class is advisable until the blood level has been determined. If the level is found to be low, then consideration can be given to resuming the earlier drug at a higher dose (CIII). 415, 448 
